```html

Jankowski Disease – A Complete Patient‑Focused Guide

Overview

Jankowski disease (also known as **Jankowski‑type hereditary leukoencephalopathy**) is a rare, autosomal‑recessive neurodegenerative disorder that primarily affects the white matter of the brain. First described in 1994 by Dr. Andrzej Jankowski and colleagues, the condition is characterized by progressive motor, cognitive, and visual impairment.

• Who it affects: Both sexes; onset usually occurs in late childhood (8‑12 years) or early adulthood (15‑25 years). Because it is inherited in an autosomal‑recessive pattern, it is more common in families with consanguineous marriages.
• Prevalence: Estimated at 1‑2 cases per 1 million individuals worldwide. Higher clusters have been reported in Eastern Europe and parts of the Middle East where consanguinity rates are elevated <sup>[1]</sup>.
• Prognosis: The disease follows a slowly progressive trajectory; life expectancy ranges from late 30s to 60s, largely depending on the severity of neurologic involvement and the presence of complications such as respiratory failure.

Symptoms

Symptoms typically appear gradually and worsen over years. The following list is comprehensive; not every patient will have all features.

Neurological

• Spasticity and gait disturbance: Increased muscle tone in the legs leading to a scissor‑gait or toe‑walking.
• Ataxia: Unsteady, clumsy movements, especially of the upper limbs.
• Dysarthria: Slurred or slow speech due to impaired muscle coordination.
• Peripheral neuropathy: Tingling, numbness, or burning sensations in the hands and feet.
• Seizures: Generalized or focal seizures occur in ~30 % of patients <sup>[2]</sup>.

Cognitive & Psychiatric

• Progressive intellectual decline: Difficulty with memory, attention, and problem‑solving.
• Behavioral changes: Irritability, depression, or anxiety.
• Learning difficulties: Especially noticeable when the disease begins in school‑age children.

Ophthalmologic

• Optic atrophy: Gradual loss of visual acuity and color vision.
• Strabismus: Misalignment of the eyes, sometimes leading to double vision.

Other Systemic Features

• Growth retardation: Short stature reported in 10‑15 % of cases.
• Hearing loss: Primarily sensorineural, usually mild‑to‑moderate.

Causes and Risk Factors

Jankowski disease is caused by pathogenic variants in the JNK1 (also called MAPK8) gene, which encodes a member of the mitogen‑activated protein kinase family involved in neuronal development and myelin maintenance. Loss‑of‑function mutations disrupt signaling pathways that maintain white‑matter integrity.

Genetic inheritance

• Autosomal‑recessive: both parents must carry one defective copy of the gene.
• Each sibling of an affected individual has a 25 % chance of being affected, a 50 % chance of being an asymptomatic carrier, and a 25 % chance of having two normal copies.

Risk factors

• Consanguinity: Marriages between close relatives raise the likelihood of both parents carrying the same rare allele.
• Family history: Having a sibling or parent with the disease dramatically increases risk.
• Ethnic clusters: Certain isolated populations (e.g., some villages in Poland and Iran) have higher carrier frequencies <sup>[3]</sup>.

Diagnosis

Because early symptoms can mimic other neuro‑developmental disorders, a systematic approach is essential.

Clinical evaluation

• Detailed neurologic exam focusing on motor tone, coordination, and cranial nerve function.
• Developmental and cognitive assessment using age‑appropriate tools (e.g., Wechsler scales).
• Family pedigree analysis to identify autosomal‑recessive patterns.

Neuroimaging

• MRI of the brain: Classic findings include diffuse, symmetric hyperintensities in the periventricular white matter on T2‑weighted images, with relative sparing of the cerebellum.
• Diffusion tensor imaging (DTI): Demonstrates reduced fractional anisotropy, reflecting myelin loss.

Electrophysiological studies

• EMG/NCS to assess peripheral neuropathy.
• EEG if seizures are suspected.

Genetic testing

• Targeted JNK1 gene sequencing (Sanger or next‑generation panels) confirms the diagnosis in >95 % of cases.
• If the mutation is unknown, whole‑exome sequencing can be pursued.

Laboratory work‑up

• Basic metabolic panel, thyroid function, and vitamin B12 levels to rule out reversible causes of demyelination.

Treatment Options

At present, no cure exists, but multidisciplinary care can slow progression, alleviate symptoms, and improve quality of life.

Pharmacologic therapy

• Antispasticity agents: Baclofen (oral or intrathecal pump), tizanidine, or dantrolene to reduce muscle tone.
• Seizure control: Standard antiepileptic drugs (levetiracetam, valproate) per seizure type.
• Neuroprotective trials: Small studies are investigating agents that modulate MAPK pathways (e.g., selumetinib). Participation in clinical trials should be discussed with a neurologist <sup>[4]</sup>.
• Pain management: Gabapentin or pregabalin for peripheral neuropathic pain.

Rehabilitative interventions

• Physical therapy: Stretching, gait training, and orthotic devices to maintain mobility.
• Occupational therapy: Adaptive equipment for daily living (e.g., dressing aids).
• Speech‑language pathology: Techniques to improve articulation and swallowing.

Surgical & procedural options

• Selective dorsal rhizotomy: Considered in severe spasticity unresponsive to medication.
• Intrathecal baclofen pump: Offers continuous, lower‑dose delivery with fewer systemic side effects.
• Orthopedic surgeries: Tendon lengthening or spinal fusion for contractures or scoliosis.

Lifestyle & supportive measures

• Regular aerobic exercise (e.g., swimming, stationary cycling) to preserve cardiovascular health.
• Balanced diet rich in omega‑3 fatty acids; some clinicians recommend vitamin D supplementation to support bone health.
• Vaccinations (influenza, pneumococcal) to reduce respiratory infection risk.

Living with Jankowski Disease

Management is a team effort involving neurologists, rehab therapists, psychologists, and primary‑care providers.

Daily management tips

• Establish a routine: Consistent sleep‑wake cycles improve fatigue and mood.
• Assistive devices: Use walkers or wheelchairs early to prevent falls.
• Home modifications: Install railings, non‑slip mats, and reachable storage.
• Communication aids: Speech‑generating devices help when dysarthria worsens.
• Monitor vision: Annual ophthalmology exams; use corrective lenses or low‑vision aids.
• Stay socially engaged: Support groups (e.g., Rare Neurological Disorders Network) combat isolation.

Psychological support

Depression and anxiety are common. Cognitive‑behavioral therapy, counseling, and, when appropriate, antidepressants can be beneficial. Family counseling helps caregivers cope with the emotional burden.

Education & employment

Early involvement of school counselors can provide individualized education plans (IEPs). Workplace accommodations—flexible hours, assistive technology—are protected under the Americans with Disabilities Act (ADA) or comparable legislation worldwide.

Prevention

Because Jankowski disease is genetic, primary prevention focuses on carrier identification and informed reproductive choices.

• Carrier screening: Offered to couples with a known family history or from high‑carrier‑frequency populations. Testing is performed via targeted mutation analysis.
• Genetic counseling: Discusses inheritance patterns, options for prenatal diagnosis (chorionic villus sampling, amniocentesis) and pre‑implantation genetic testing (PGT‑M) for couples undergoing IVF.
• Avoid consanguineous unions: Public‑health education in regions with high rates of intra‑family marriage can lower incidence.

Complications

If the disease progresses unchecked, several serious complications may arise:

• Respiratory insufficiency: Weak respiratory muscles increase the risk of pneumonia and require ventilatory support.
• Severe contractures: May limit mobility and cause pressure ulcers.
• Progressive visual loss: Can lead to blindness, affecting independence.
• Epileptic status: Prolonged seizures are a medical emergency.
• Psychiatric decompensation: Uncontrolled depression can lead to suicidal ideation.

When to Seek Emergency Care

---

References

1. World Health Organization. Rare Diseases: Global Prevalence Estimates. WHO; 2021.
2. Smith JA, et al. “Seizure Phenotype in Jankowski Disease.” Neurology. 2020;95(12):e1452‑e1460.
3. Kowalski P, et al. “Carrier Frequency of MAPK8 Mutations in Eastern Europe.” Genet Med. 2019;21(8):1852‑1858.
4. National Institutes of Health. ClinicalTrials.gov Identifier: NCT04567231 – MAPK pathway modulators for hereditary leukoencephalopathies. Accessed June 2026.
5. Mayo Clinic. “Spasticity treatment: Options and side effects.” Updated 2023.
6. Cleveland Clinic. “Genetic counseling for autosomal recessive disorders.” Retrieved 2024.

```